Bristol-myers Squibb Stock News

Riding the Oracle of Omaha's coattails is often a moneymaking proposition.

Oregon Public Employees Retirement Fund lifted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 6.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 665,062 shares of the biopharmaceutical companys stock after purchasing an additional 40,459 shares during the quarter. Oregon Public []

Bristol Myers Squibb Co. was sued Wednesday by four employees who said the drugmaker refused to grant them religious exemptions from its COVID-19 vaccination requirement and threatened to fire them on Dec. 6 for remaining unvaccinated.

A Covid-19 antibody treatment developed by GlaxoSmithKline and Vir Biotechnology was effective against the Omicron variant in early laboratory studies.

Pinnacle Associates Ltd. trimmed its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.1% during the third quarter, HoldingsChannel reports. The firm owned 306,540 shares of the biopharmaceutical companys stock after selling 13,232 shares during the quarter. Pinnacle Associates Ltd.s holdings in Bristol-Myers Squibb were worth $18,138,000 at the end of the most recent quarter. []

Bristol Myers Squibb Co was sued on Wednesday by four employees who said the drugmaker has refused their requests for religious exemptions from getting COVID-19 vaccines, and threatened to fire them n

BLB&B Advisors LLC lifted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 6.8% in the third quarter, according to its most recent filing with the SEC. The firm owned 58,998 shares of the biopharmaceutical companys stock after acquiring an additional 3,743 shares during the period. BLB&B Advisors LLCs holdings in Bristol-Myers Squibb were worth []

The B Cell Receptor Inhibitor Market report is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The research analysts

Crew Capital Management Ltd. lowered its position in Bristol-Myers Squibb (NYSE:BMY) by 2.1% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 11,683 shares of the biopharmaceutical companys stock after selling 250 shares during the period. Crew Capital Management Ltd.s holdings in Bristol-Myers Squibb were worth $691,000 []

Bristol Myers' (BMY) applications seeking approval for deucravacitinib are accepted by the regulatory bodies of both the United States and the European Union.

NEW YORK , Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAL, CCL, TWTR, BMY, and XPEV. Full story available on Benzinga.com

On CNBCs "Mad Money Lightning Round," Jim Cramer said with Matterport, Inc. (NASDAQ: MTTR ) already moving too

The global Bladder Cancer market size is projected to a CAGR of 3.7% during 2021-2027. The elements, for example, a rising rate of bladder disease, expansion in mindfulness about malignant growth and their accessible treatments, developing medical services use, extending

Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead. The post 7 Drug Stocks to Buy Now While They're Still on Sale appe

RMR Wealth Builders lifted its position in Bristol-Myers Squibb (NYSE:BMY) by 6.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 6,170 shares of the biopharmaceutical companys stock after purchasing an additional 356 shares during the quarter. RMR Wealth Builders holdings in Bristol-Myers Squibb were []